Bethanidine

Summary

Bethanidine (CHEMBL1201260) is an approved small-molecule adrenergic antagonist (ATC C02CC01); indicated across 1 condition including hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C02CC01
• Indications: 1 condition
• Chemistry: 177.25 Da · C10H15N3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201260
Name	Bethanidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2368
ChEBI	CHEBI:37937
ATC	C02CC01
Molecular formula	C10H15N3
Molecular weight	177.25
InChIKey	NIVZHWNOUVJHKV-UHFFFAOYSA-N

SMILES: CNC(=NC)NCC1=CC=CC=C1

IUPAC name: 1-benzyl-2,3-dimethylguanidine

Pharmacological roles (ChEBI): adrenergic antagonist, antihypertensive agent.

Also known as: Betanidina, Betanidine, Bethanidine, BETHANIDINE, betanidine

Parent form; salt/anhydrous children: CHEMBL2110368

Patent coverage: 1,182 distinct patent families (3,816 SureChEMBL compound mentions), from 3 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).